HomeTagsNMPA

NMPA

Biotechnology

InnoCare Announces Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

Business Wire - September 6, 2022

InnoCare Pharma, a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that BTK inhibitor orelabrutinib has been granted priority review...

Biotechnology

IASO Biotherapeutics’ Equecabtagene Autoleucel, the World’s First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA

PR Newswire - May 31, 2022

IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced that China's National...